High‑quality exosome isolation, at scale
Vezics is a highly efficient, scalable chromatography platform purpose‑built for high‑quality extracellular vesicle (EV) isolation across body fluids. Service available now; laboratory instrument in development.
Designed for reproducible purity & yield
Pharmahungary Group quality system
What is Vezics?
A novel SEC‑based platform engineered to retain the advantages of size‑exclusion chromatography while eliminating its main drawbacks for EV isolation. High‑quality isolation is foundational for downstream research, diagnostic and therapeutic applications.
Summary
Reliable, reproducible exosome isolation remains a major challenge. While SEC is increasingly used, off‑the‑shelf solutions are not optimized for EVs. Vezics aims to solve this with a chromatography platform tailored for EV isolation, addressing purity, yield and scalability.
High purity
Clean EV fractions suitable for proteomic/genomic analyses.
Reproducible
Consistent results across runs and body fluids.
Scalable
Adaptable to varying input volumes and sample matrices.
Technology at a glance
Two‑stage overview and a simple sample‑to‑results pathway.
1) SEC‑based isolation
Chromatography media and columns tuned to input material for efficient EV separation.
2) Optional characterization
Biomarker‑based EV characterization panels available on request (research‑use only).
Services
EV Isolation Service (available now)
We isolate extracellular vesicles from your samples (animal or human body fluids such as blood, urine, etc.) and ship the isolated EVs back to your lab.
Research‑use only.
Instrument (in development)
A Vezics laboratory system with dedicated chromatography columns tailored to body fluid types.
Why Vezics
Our ISO 9001:2015–certified R&D services combine deep expertise in extracellular vesicle (EV) biology, preparative chemistry, and comprehensive physicochemical and biological characterization of therapeutic agents, supported by strong regulatory affairs competence. We provide reliable, industry-grade solutions tailored to the development and analytical validation of complex biological and chemical entities, ensuring robust, reproducible, and compliant outcomes. Our services are ideally suited both for industrial applications—including preclinical development, process optimization, and quality control—and for the rigorous validation of academic research results, delivering data and documentation that meet international quality standards and facilitate successful translation from research to real-world application.
Selected Publications
- Kovácsházi, Hambalkó et al., Sci Rep (2024) — PMID: 38797778 — View on PubMed -Application of EVs isolated by VEZICS platform, demonstrating feasibility of biomarker discovery. This paper also demonstrates EV functional characterization technologies.
- Pecan, Hambalkó al., Int J Mol Sci (2020) — PMID: 33081396 — View on PubMed - Demonstration of manufacturing therapeutic EVs with immunomodulatory and cytoprotective properties.
- Onódi et al., Front Physiol (2018) — PMID: 30405435 — View on PubMed -First demonstration of VEZICS EV isolation platform, describing proof of concept of high-purity EV isolation from rodent blood plasma.
- Sluijter et al., Cardiovasc Res (2017) — PMID: 29106545 — View on PubMed - Well-accepted position paper on EV diagnostics and therapeutics in the cardiovascular field. Giricz et al., J Mol Cell Cardiol (2014) — PMID: 24440457 — View on PubMed - First demonstration of major role of EVs in cardioprotective interventions.
Contact
Pharmahungary Group
Graphisoft Park,
7 Záhony street, Budapest,
H‑1031, Hungary — EU
Email: [email protected]
Calls by prior e‑mail scheduling only.